



Starting NEMLUVIO made simple



Actor portrayal.

Important Safety Information

Indication: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis. **Contraindication:** Known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

Please see Important Safety Information throughout, accompanying full Prescribing Information including Patient Information, or visit nemluviohcp.com.

GPS[★] for nemludio™

GALDERMA PATIENT SERVICES

Your patient's real-time navigation partner
to help guide them to success

GPS (Galderma Patient Services) for NEMLUVIO™ helps patients start and stay on treatment by helping to navigate coverage and providing access to assistance programs and adherence support. Enroll your patients today.



Actor portrayal.

3 simple steps to get patients on NEMLUVIO

- 1 Complete Enrollment Form with patient consent
- 2 Send the completed Enrollment Form to the in-network specialty pharmacy (SP) of choice or Hub
- 3 Confirm eligibility and patient receives NEMLUVIO right to their door*

Completing an Enrollment Form is easy for you and your staff:



Fill out an Enrollment Form (enclosed), and fax it to Galderma at 1-844-636-5884

OR



Enroll patients online at nemluviohcp.com/GPsenrollment

*Initial shipping location varies based on provider/office/patient preference.

Eligible patients will receive Quick Start if additional steps are required for prior authorization.

Services to help them start therapy

Quick Start

Provides first/loading dose of NEMLUVIO at no cost for eligible patients whose treatment is impacted by a delay in coverage.

Note: Be sure to fill out the Free Goods Rx within the Enrollment Form to make sure your patients can get started quickly.

Patient Welcome Kit

This helpful kit is sent directly to patients that opted in during enrollment. It includes starter materials, Galderma Skincare Cetaphil® samples, and an overview of key GPS for NEMLUVIO support programs.

Patient Assistance Program

Helps patients who financially qualify gain access to treatment when they don't have coverage or have insufficient/limited coverage for NEMLUVIO.

Nurse Navigator Support

Nurse Navigators are available online or in person to provide live injection training, injection assistance, and ongoing disease management support to your patients.

Note: While filling out the Enrollment Form, you may sign your patients up for Nurse Navigator support with their consent.

Support to help them stay on track

Co-Pay Assistance

Eligible patients may pay as little as \$0[†]

The Co-Pay program helps commercially insured patients reduce or eliminate out-of-pocket costs and improve affordability.

Replacement Product Program

Offers replacement dose(s) of NEMLUVIO due to product defect or error during administration.

Bridge

Prevents a gap in treatment for eligible patients who have a temporary loss of insurance coverage.

Sharps Disposal Program

Ensures that patients who prefer a convenient mail-back option can properly dispose of NEMLUVIO self-injectable pens.

Get patients started quickly and seamlessly with GPS for NEMLUVIO.

Learn more at nemluviohcp.com/GPSenrollment

[†]Out-of-pocket cost reductions for eligible patients may vary. The annual maximum for co-pay assistance is set at \$15,000.

Our Patient Feedback Tool gives you answers

Patients taking NEMLUVIO for the first time will have important feedback to share. Let Galderma give you a glimpse into the fast and lasting relief¹ of NEMLUVIO through our Patient Feedback Tool. It's a service that allows you to hear firsthand from patients and learn how they are responding as they progress toward treatment success.

Patients can sign up by scanning the QR code on the Journey to Recovery flashcard.

Reference: 1. Galderma Laboratories, L.P.; data on file.

Important Safety Information

Warnings/Precautions: Hypersensitivity reactions have been reported with NEMLUVIO use. If a clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO. **Adverse Events:** Most common adverse reactions (incidence $\geq 1\%$) are headache, dermatitis atopic, eczema, and eczema nummular.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see accompanying full Prescribing Information, including Patient Information or visit nemluviohcp.com.

GALDERMA

©2024 Galderma Laboratories, L.P. All Rights Reserved.

NEMLUVIO is a registered trademark of Galderma.

US-NPN-2400045 08/24